Pfizer’s U.S. Overhaul Is Paying Off, But Work Is Not Done – CEO Kindler

Pfizer's "fast-to-market" execution of Lyrica for fibromyalgia is evidence the company is already seeing the benefits of its new U.S. business structure, according to CEO Jeffrey Kindler